Table 1. Summary of tumor types screened by High Resolution Melt Curve Analysis (HRM).
Total cases nā=ā752 (excluding controls) | Normal by HRM | Confirmed positive for FOXL2 c.402C>G mutation out of HRM positive cases | |
Ovarian cancer negative controls | 14 | 11 | 0/3* |
Ovarian A-GCT positive controls (including an unreported A-GCT case and the A-GCT cell line, KGN) | 13 | 0 | 13/13 |
Bladder Cancer | 40 | 40 | |
Breast Cancer | 74 | 71 | 0/3* |
Carcinoid Cancer | 8 | 8 | |
Cervical Cancer | 16 | 16 | |
Colorectal Cancer | 77 | 75 | 0/2* |
Endometrial Cancer | 12 | 12 | |
Esophageal Cancer | 21 | 21 | |
Gastric Cancer | 90 | 89 | 0/1* |
Head & Neck Cancer | 28 | 26 | 0/2* |
Hepatic (HCC & Cholangiocarcinoma) | 14 | 14 | |
Lung Cancer (All types) | 125 | 123 | 0/2* |
Melanoma | 31 | 31 | |
Ovarian Cancer | 32 | 32 | |
Pancreatic Cancer | 4 | 4 | |
Prostate Cancer | 37 | 37 | |
Renal Cancer | 52 | 51 | 0/1* |
Leiomyosarcoma | 15 | 15 | |
Malignant fibrous histiocytoma-pleomorphic sarcoma | 8 | 8 | |
Rhabdomyosarcoma | 2 | 2 | |
Liposarcoma | 4 | 4 | |
Fibrosarcoma | 1 | 1 | |
Testicular Cancer | 19 | 18 | 0/1* |
Thyroid Cancer | 42 | 42 |
Sequence data is available for all screen positive samples.
Variants seen on HRM screen but not confirmed by sequencing (HRM false positive results).